Educational program to reduce major bleeding in patients undergoing percutaneous coronary interventions and receiving abciximab.
Division of Pharmacy, St. Louis College of Pharmacy (SLCP), 4588 Parkview Place, St. Louis, MO 63110, USA. pdobesh@stlcop.edu
Paul P
PP
Dobesh
Jonathan E
JE
Lakamp
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000925:Anticoagulants / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced* / Q000191:economics / Q000517:prevention & control*; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010353:Patient Education as Topic; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D012189:Retrospective Studies
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D000077284:Abciximab